Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $162,000.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 100,000 shares of the business’s stock in a transaction dated Thursday, November 14th. The shares were acquired at an average price of $1.62 per share, for a total transaction of $162,000.00. Following the acquisition, the chief executive officer now directly owns 211,612,405 shares in the company, valued at $342,812,096.10. This represents a 0.05 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The shares were bought at an average price of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Stock Up 1.2 %

Shares of OPK stock opened at $1.64 on Friday. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.75. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The firm has a market cap of $1.12 billion, a PE ratio of -8.63 and a beta of 1.65. The stock has a 50 day moving average of $1.52 and a 200-day moving average of $1.43.

Institutional Trading of OPKO Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its stake in shares of OPKO Health by 23.7% in the first quarter. BNP Paribas Financial Markets now owns 336,315 shares of the biotechnology company’s stock valued at $404,000 after buying an additional 64,443 shares during the period. Headlands Technologies LLC acquired a new stake in shares of OPKO Health during the 1st quarter worth approximately $47,000. Lazard Asset Management LLC bought a new stake in shares of OPKO Health during the first quarter valued at approximately $258,000. Price T Rowe Associates Inc. MD raised its stake in shares of OPKO Health by 4.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock valued at $536,000 after purchasing an additional 17,671 shares in the last quarter. Finally, AWM Investment Company Inc. lifted its position in OPKO Health by 18.2% in the first quarter. AWM Investment Company Inc. now owns 1,300,000 shares of the biotechnology company’s stock worth $1,560,000 after purchasing an additional 200,000 shares during the period. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Thursday, September 26th. Piper Sandler reiterated an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a report on Tuesday, September 17th. StockNews.com raised shares of OPKO Health to a “sell” rating in a report on Saturday, July 27th. Finally, Barrington Research reiterated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a report on Friday, November 8th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.